Medarex, Inc. will receive a milestone payment for an undisclosed amount from its licensing partner, Novo Nordisk A/S. The payment is a result of the submission of an IND by Novo Nordisk for the clinical development of an antibody generated by Medarex’s UltiMAb technology. Medarex may receive future milestone payments and royalties should the product candidate progress through clinical development and to the market. “We are pleased with the milestone achieved by Novo Nordisk and l...